According to the results of a recent trial, an inhalable COVID-19 vaccination offers significant protection for the lungs against coronavirus. Vaccines that may be self-administered using an inhaler and that are shelf-stable for up to three months at room temperature were developed by researchers at North Carolina State University in the United States.
Many vaccination doses have previously been licensed for use in the US and throughout the globe, but researchers wanted to see if they could get around some of the difficulties associated with injecting a vaccine into muscles.
Taking the vaccination intramuscularly is less efficient at delivering it to the lungs, which reduces its effectiveness. mRNA vaccines, in their present format, need cold storage and delivery by qualified medical staff in order to be effective against COVID-19. In the event of a pandemic, a vaccination that is stable at room temperature and can be self-administered would dramatically minimize patient wait times and medical staff stress. In order for it to operate through inhalation, you’ll have to rework the delivery method.
There are two types of exosomes that may be used to administer vaccines: LSC Exo (lung-derived) and LSC-Exo (nanosized vesicles that have recently been identified as a good mechanism of drug administration).
As reported in the Extracellular Vesicle journal, lung-derived nanoparticles were shown to be more successful than synthetic liposome particles in delivering mRNA and protein payload to bronchioles and deep lung tissue.
The inhalable, protein-based, virus-like particle (VLP) vaccine was then tested in rodents using the SARS-CoV-2 viral spike protein. Antibodies created by the inhalable vaccination were able to identify the virus. When the animals were exposed to COVID-19 after receiving two doses, the antibodies protected them. Exosome synthesis and purification have shown encouraging results so far, but there are some difficulties that may develop if production and purification are scaled up.